Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Status:
Recruiting
Trial end date:
2021-12-16
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well ixazomib and dexamethasone or ixazomib,
dexamethasone, and lenalidomide work based on the presence of the rearrangement of a gene
called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NFKB2) in
treating patients with multiple myeloma that has returned after a period of improvement or
does not respond to treatment. Ixazomib may stop the growth of cancer cells by blocking
enzymes called proteasomes needed for cell growth. Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide
may stimulate the immune system against cancer cells and may also prevent the growth of new
blood vessels that tumors need to grow. It is not yet known whether ixazomib and
dexamethasone, or ixazomib, dexamethasone, and lenalidomide are more effective in treating
multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Millennium Pharmaceuticals, Inc. Multiple Myeloma Research Consortium